Karen G Potter
Morrison & Foerster LLP
Articles
The “big bang” for sequence listings: new requirements in place July 1, 2022
USA - May 12 2022 Life sciences patent applications often contain DNA, RNA, and amino acid sequences in the specification, claims, or figures that are required to be…
Casting a New Light on Diagnostic Patents: “Methods of Preparation” Patent-Eligible
USA - August 12 2020 The ability of life sciences companies to rely on patent protection for diagnostic methods has been eroded over the last ten years, although…
AI Patent Policy
USA - August 27 2019 On August 26, 2019, Laura Peter, the Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the USPTO, posted an update…
Patent Eligibility in the Life Sciences: Supreme Court Declines Review of Ariosa Diagnostics v. Sequenom
USA - June 30 2016 On June 27, 2016, the U.S. Supreme Court denied certiorari in Ariosa Diagnostics, Inc. v. Sequenom, Inc., thereby letting stand the Federal Circuit's…
USPTO Issues New Subject Matter Eligibility Examples for Life Sciences
USA - May 12 2016 The United States Patent and Trademark Office (USPTO) recently provided updated guidance regarding the patent eligibility of subject matter related…
